Category
Tafamidis
CAS Number
951395-08-7
Molecular Formula
C₂₁H₂₄Cl₂N₂O₈
Molecular Weight
503.33 g/mol
Synonym

2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; D-Glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate;D-Glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate;Vyndaqel

Keywords
Pharmaceutical Standards
Metabolites.
Impurities
slide.1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Tafamidis meglumine is the salt form of tafamidis used as a medication for transthyretin amyloidosis (ATTR). It works by stabilizing the transthyretin (TTR) protein, preventing it from misfolding and forming amyloid deposits that damage the heart and nerves. The meglumine form improves the drug’s solubility and bioavailability, making it suitable for oral administration. It is used to slow disease progression in both hereditary and cardiac forms of ATTR.